Daily Archives: January 15, 2023
2023 ASA Guidelines for preoperative fasting
15 Jan, 2023 | 20:42h | UTC
WHO updates COVID-19 guidelines on masks, treatments and patient care
15 Jan, 2023 | 20:44h | UTCWHO updates COVID-19 guidelines on masks, treatments and patient care – World Health Organization
WHO Updated Guidelines:
Therapeutics and COVID-19: Living guideline, 13 January 2023 – World Health Organization
Cohort Study | Adverse events identified in nearly one in four hospital admissions
15 Jan, 2023 | 20:40h | UTCThe Safety of Inpatient Health Care – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Nearly 1 in 4 Hospital Patients Have Harmful Event During Their Stay – HealthDay
Commentary on Twitter
A retrospective cohort study assessed patient safety in 11 Massachusetts hospitals in 2018. Adverse events were identified in 24% of hospital admissions and preventable adverse events in 7%. https://t.co/o4JM4JbxSF pic.twitter.com/yPSnvXM5IR
— NEJM (@NEJM) January 13, 2023
Review | Long COVID: major findings, mechanisms and recommendations
15 Jan, 2023 | 20:34h | UTCLong COVID: major findings, mechanisms and recommendations – Nature Reviews Microbiology
A survey of COVID-19 vaccine acceptance across 23 countries in 2022
15 Jan, 2023 | 20:33h | UTCA survey of COVID-19 vaccine acceptance across 23 countries in 2022 – Nature Medicine
News Release: Global COVID-19 vaccine acceptance rising but hesitancy remains – London School of Hygiene & Tropical Medicine
Commentary on Twitter
The third annual iteration of a survey assessing vaccine confidence in 23 countries shows the overall willingness to accept a COVID-19 vaccine has increased, although results were heteregeous across countries, according to a @NatureMedicine paper. https://t.co/0EkMH7oRdn pic.twitter.com/bLc98F9AYt
— Nature Portfolio (@NaturePortfolio) January 13, 2023
RCT | Fluvoxamine no better than placebo in outpatients with mild to moderate COVID-19
15 Jan, 2023 | 20:37h | UTCEditorial: Lack of Benefit of Fluvoxamine for COVID-19 – JAMA
Author Interview: Fluvoxamine vs Placebo and Time to Sustained Recovery From Mild or Moderate COVID-19 – JAMA
Commentary: Trial finds that fluvoxamine doesn’t speed COVID recovery – CIDRAP
Commentary on Twitter
Among outpatients with mild to moderate #COVID19, treatment with 50 mg of fluvoxamine twice daily for 10 days, compared with placebo, did not improve time to sustained recovery. https://t.co/4QgBssqFSU pic.twitter.com/RMZ6mqlx6u
— JAMA (@JAMA_current) January 12, 2023
Best infectious diseases articles from 2022 – A year end review of non-COVID literature
15 Jan, 2023 | 20:31h | UTC
Commentary on Twitter
??NEW ??
Our new post, a great collaboration w ? @IDstewardship
Best Infectious Diseases Articles From 2022 – A Year End Review Of Non-COVID Literature
1️⃣7️⃣⚡️? RCTs @NEJM @TheLancet ✨
2️⃣syst Rev
3️⃣?Guidelines @Wiki_Guidelines
#IDTwitter #TwitteRxhttps://t.co/JL07NLa3BV pic.twitter.com/Qcf2cwK8Sd— Antibiotic Steward Bassam Ghanem?? (@ABsteward) January 4, 2023
M-A | Effect of breathwork on stress and mental health
15 Jan, 2023 | 20:28h | UTC
Commentary on Twitter
A meta-analysis in @SciReports shows that breathwork may be effective for improving stress and mental health. The authors also call for nuanced research approaches with low risk-of-bias study designs to avoid a miscalibration between hype and evidence. https://t.co/iTLGE2AsPT pic.twitter.com/SM5FBL2idK
— Nature Portfolio (@NaturePortfolio) January 12, 2023
Cohort Study | Trends in antipsychotic prescribing to children and adolescents in England
15 Jan, 2023 | 20:26h | UTCNews Release: Researchers reveal worrying rise in antipsychotic prescriptions for children and young people – University of Manchester
Commentary on Twitter
"From 2000 to 2019, the prescriptions for antipsychotics for children and adolescents in England doubled from an annual period prevalence in 2000 of 0·057% (95% CI 0·052–0·063%) to 0·105% (0·100–0·111%) in 2019"
New research Article @FBMH_UoM @GMMH_NHS https://t.co/ukXkSVfhtI
— The Lancet Psychiatry (@TheLancetPsych) January 11, 2023
UK National case series of group A streptococcus pleural empyema in children: clinical and microbiological features
15 Jan, 2023 | 20:24h | UTC
Commentary from the author on Twitter (thread – click for more)
huge amount of recent interest in invasive group A streptococcus (iGAS) infection in children
but up until now little patient-level clinical data on this spike in cases
we hope our case series @TheLancetInfDis will help address this knowledge gap https://t.co/75kV7FVmST 1/n pic.twitter.com/ytKyRu8MYi— Thomas Christie Williams (@Williams_T_C) January 10, 2023
ESMO Guideline | Venous thromboembolism in cancer patients
15 Jan, 2023 | 20:21h | UTCVenous thromboembolism in cancer patients: ESMO Clinical Practice Guideline – Annals of Oncology
Related:
Cancer-associated venous thromboembolism – Nature Reviews Disease Primers
Infographic: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.
AHA Scientific Statement | Palliative care across the life span for children with heart disease
15 Jan, 2023 | 20:19h | UTCTop Things to Know: Palliative Care Across Lifespan for Children With Heart Disease – American Heart Association
Commentary: Palliative Care Across the Lifespan for Children with Heart Disease – American Heart Association
M-A | Transfusion guidelines in traumatic brain injury
15 Jan, 2023 | 20:15h | UTC
Consensus Paper | Revision of classification system for reporting on skin biopsies of melanocytic lesions
15 Jan, 2023 | 20:17h | UTCCommentaries:
MPATH-Dx Version 2.0 Simplifies Classification of Melanoma – HealthDay
Commentary on Twitter
American and international #dermatopathologists revise Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis schema. MPATH-Dx V2.0 improves standardized diagnostic reporting and patient management of #melanoma. https://t.co/G0fluzq5fs
— JAMA Network Open (@JAMANetworkOpen) January 12, 2023
RCT | Ecopipam for Tourette Syndrome
15 Jan, 2023 | 20:09h | UTCEcopipam for Tourette Syndrome: A Randomized Trial – Pediatrics
Commentary: Ecopipam May Reduce Tics in Children With Tourette Syndrome – Psychiatric News Alert
Commentary on Twitter
Ecopipam, a selective D1-like receptor antagonist, is in development for children & adolescents with Tourette syndrome. Can ecopipam achieve a clinically meaningful reduction in tics without the disadvantages of D2-like receptor antagonists? https://t.co/GXxnPsP74C #Pediatrics pic.twitter.com/14fwu4npJi
— AAP Pediatrics (@aap_peds) January 11, 2023
SR | Baclofen for alcohol use disorder
15 Jan, 2023 | 20:11h | UTCBaclofen for alcohol use disorder – Cochrane Library
Summary: Baclofen for alcohol use disorder – Cochrane Library
Synopsis | Endocrine Society hypercalcemia of malignancy guidelines
15 Jan, 2023 | 22:13h | UTCEndocrine Society Hypercalcemia of Malignancy Guidelines – JAMA Oncology (free for a limited period)
Original article: Guideline | Treatment of hypercalcemia of malignancy in adults
RCT | Lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis
15 Jan, 2023 | 20:07h | UTC
Commentary on Twitter
Does blocking the IL-13 cytokine w/ lebrikizumab combined w/ topical therapy provide clinical benefit in atopic eczema? This study reflecting real-world use patterns suggests a benefit. https://t.co/apUvYO3Jqv
— JAMA Dermatology (@JAMADerm) January 13, 2023
RCT | MRI–guided vs. CT–guided stereotactic body radiotherapy for prostate cancer
15 Jan, 2023 | 20:05h | UTC
Commentary from the author on Twitter (thread – click for more)
Pleased to share the primary endpoint results of the randomized phase III MIRAGE trial evaluating whether aggressive margin reduction with MRI-guidance leads to reduced toxicity in the context of prostate SBRT, out today in @JAMAOncology https://t.co/5ZKElUR4uk (1/n)
— Amar Kishan (@AmarUKishan) January 12, 2023
RCT | In patients undergoing cardiac surgery, intravenous high-dose selenium did not reduce morbidity or mortality
15 Jan, 2023 | 20:00h | UTC
Commentary on Twitter
In this study, high-dose sodium selenite was not effective in reducing the development of organ dysfunction and death in high-risk cardiac surgery patients. @CStoppe @CriticalCa https://t.co/H3HR1u1HhU
— JAMA Surgery (@JAMASurgery) January 12, 2023
M-A | Outcomes and complications of pars plana vitrectomy for tractional retinal detachment in people with diabetes
15 Jan, 2023 | 20:02h | UTCCommentary: Pars Plana Vitrectomy Associated with High Retinal Reattachment, but Low Final Vision – HCP Live
Commentary on Twitter
Study findings suggest that pars plana vitrectomy is associated with high anatomic reattachment but limited final vision postoperatively, which may be useful for the counseling of patients with diabetic tractional retinal detachment. https://t.co/Comj3VOpUF
— JAMA Ophthalmology (@JAMAOphth) January 12, 2023
M-A | Costs and clinical benefits of enhanced recovery after surgery (ERAS) in pancreaticoduodenectomy
15 Jan, 2023 | 19:58h | UTCRelated:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Crossover RCT | Preliminary study showed closed-loop insulin delivery might improve glycemic control in some adults with Type 2 DM
15 Jan, 2023 | 19:56h | UTCNews Release: Artificial pancreas successfully trialed for use by type 2 diabetes patients – University of Cambridge
Commentary: Artificial Pancreas Device May Help Folks With Type 2 Diabetes – HealthDay
RCT | Cosmetic results and side effects of accelerated partial-breast irradiation vs. whole-breast irradiation for low-risk invasive carcinoma of the breast
15 Jan, 2023 | 19:53h | UTCCosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter
5yr results of the phase 3 #IRMAtrial: EBRT #APBI b.i.d. associated with slightly increased rate of moderate soft tissue and bone toxicity and a slightly inferior cosmesis, though overall toxicity was in an acceptable range @JCO_ASCO #BCSM @OncoAlert https://t.co/8LHE2ut3t2
— Bruno Meduri (@brunomeduri) January 9, 2023
RCT | High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer
15 Jan, 2023 | 19:51h | UTCHigh-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538 – Journal of Clinical Oncology (link to abstract – $ for full-text)